| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FBXO2 |
| Uniprot No | Q9UK22 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-296aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMDGDGDP ESVGQPEEAS PEEQPEEASA EEERPEDQQE EEAAAAAAYL DELPEPLLLR VLAALPAAEL VQACRLVCLR WKELVDGAPL WLLKCQQEGL VPEGGVEEER DHWQQFYFLS KRRRNLLRNP CGEEDLEGWC DVEHGGDGWR VEELPGDSGV EFTHDESVKK YFASSFEWCR KAQVIDLQAE GYWEELLDTT QPAIVVKDWY SGRSDAGCLY ELTVKLLSEH ENVLAEFSSG QVAVPQDSDG GGWMEISHTF TDYGPGVRFV RFEHGGQDSV YWKGWFGARV TNSSVWVEP |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FBXO2重组蛋白的3篇模拟参考文献及其摘要概括(基于公开研究内容整合，非真实文献)：
1. **"FBXO2 Mediates Substrate-Specific Ubiquitination via Its Recombinant F-Box Domain"**
*作者：Zhang, L. et al.*
**摘要**：本研究利用重组表达的FBXO2蛋白，揭示了其F-box结构域与特定糖基化底物的结合机制，证明其在SCF复合体中通过识别异常糖基化蛋白并介导其泛素化降解的功能。
2. **"Structural Insights into FBXO2 Recombinant Protein in Substrate Recognition"**
*作者：Kim, S. & Patel, R.*
**摘要**：通过X射线晶体学解析重组FBXO2蛋白的结构，发现其C端结构域中的疏水口袋对结合N-连接糖蛋白底物至关重要，为开发靶向FBXO2的分子工具提供理论基础。
3. **"Recombinant FBXO2 Expression in Cancer Cell Proteostasis Regulation"**
*作者：Guo, Y. et al.*
**摘要**：在肺癌细胞中过表达重组FBXO2蛋白，证实其通过降解致癌糖蛋白(如PD-L1前体)抑制肿瘤生长，提示FBXO2在癌症治疗中的潜在应用价值。
4. **"In Vitro Reconstitution of FBXO2-Dependent Ubiquitination Using Purified Recombinant Components"**
*作者：Thompson, J. et al.*
**摘要**：通过纯化的重组FBXO2、Skp1、Cul1及Rbx1蛋白，体外重建SCF^{FBXO2}泛素连接酶活性，验证其对模型底物(如溶菌酶突变体)的特异性泛素化能力。
注：以上文献为示例性质，实际引用时需以真实发表论文为准。
FBXO2 (F-box protein 2) is a member of the F-box protein family, which functions as a substrate-recognition component of the SCF (Skp1-Cul1-F-box) E3 ubiquitin ligase complex. This complex mediates the ubiquitination of specific target proteins, marking them for degradation by the proteasome. FBXO2 is notably expressed in tissues with high secretory activity, such as the liver, pancreas, and brain, where it plays a role in quality control by targeting improperly folded glycoproteins. It specifically recognizes N-linked glycans with high-mannose structures, a feature common in immature or misfolded proteins within the endoplasmic reticulum (ER). This interaction facilitates the ER-associated degradation (ERAD) pathway, maintaining cellular protein homeostasis.
Recombinant FBXO2 protein is engineered for in vitro studies to elucidate its structural and functional properties. Produced using expression systems like Escherichia coli or mammalian cell cultures, the recombinant form often includes affinity tags (e.g., GST, His-tags) for purification. Researchers utilize it to investigate substrate binding mechanisms, enzymatic activity within the ubiquitination cascade, and interactions with co-factors like Skp1. Its role in diseases, including neurodegeneration (e.g., Alzheimer’s) and cancer, has spurred interest in developing FBXO2-targeted therapies. Dysregulation of FBXO2 is linked to impaired protein clearance, contributing to pathological protein aggregation.
Studies with recombinant FBXO2 also aim to identify small-molecule modulators or peptide inhibitors that could regulate its activity, offering potential therapeutic avenues. Its involvement in metabolic disorders and viral infection pathways further underscores its biomedical relevance. By enabling detailed biochemical and structural analyses, recombinant FBXO2 serves as a critical tool for advancing understanding of ubiquitin-proteasome system dynamics and developing targeted interventions for protein homeostasis-related diseases.
×
